ARROW Endurance™ Extended Dwell Peripheral Catheter System Receives FDA Market Clearance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Brean Capital Raises Price Target on Teleflex (TFX) to $145 Following 2Q Results
July 31, 2015 7:24 AM EDTBrean Capital reiterated a Buy rating on Teleflex (NYSE: TFX), and raised the price target to $145.00 (from $135.00), following 2Q results. Teleflex reported 2Q15 adjusted EPS of $1.42, in line with consensus. Revenue was in line with expectations at $452.1 million, versus consensus estimate of $453 million.
Analyst Jason Wittes commented, "Teleflex reported 2Q15 adjusted EPS of $1.42, in line with consensus of $1.42 and $0.02 above our $1.40 estimate,... More
